Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
12. lappuse
... ingredients of a new drug to be available for tests of hypersensitivity to such ingredients and therefore will not object ... ingredient in a marketed new drug and is not one that is an ingredi- ent solely in a new drug that is legally ...
... ingredients of a new drug to be available for tests of hypersensitivity to such ingredients and therefore will not object ... ingredient in a marketed new drug and is not one that is an ingredi- ent solely in a new drug that is legally ...
34. lappuse
... ingredient ( active or inactive ) in drug products . ( 7 ) Cobalt preparations intended for use by man . ( 8 ) Intrauterine devices for human use for the purpose of contraception that incorporate heavy metals , drugs , or other active ...
... ingredient ( active or inactive ) in drug products . ( 7 ) Cobalt preparations intended for use by man . ( 8 ) Intrauterine devices for human use for the purpose of contraception that incorporate heavy metals , drugs , or other active ...
42. lappuse
... ingredients that can be generally recognized as safe and effective for use as OTC daytime sedatives . ( b ) Any OTC drug product that is la- beled , represented , or promoted as an OTC daytime sedative ( or any similar or related ...
... ingredients that can be generally recognized as safe and effective for use as OTC daytime sedatives . ( b ) Any OTC drug product that is la- beled , represented , or promoted as an OTC daytime sedative ( or any similar or related ...
43. lappuse
... ingredients , or any other ingredi- ent , for OTC use as an aphrodisiac . La- beling claims for aphrodisiacs for OTC ... ingredient for OTC oral use as an insect repellent . Labeling claims for OTC orally administered insect repel- lent ...
... ingredients , or any other ingredi- ent , for OTC use as an aphrodisiac . La- beling claims for aphrodisiacs for OTC ... ingredient for OTC oral use as an insect repellent . Labeling claims for OTC orally administered insect repel- lent ...
44. lappuse
... ingredient offered for use as a topically applied hormone cannot be considered gen- erally recognized as safe and effective for its intended use . The intended use of the product may be inferred from the product's labeling , promotional ...
... ingredient offered for use as a topically applied hormone cannot be considered gen- erally recognized as safe and effective for its intended use . The intended use of the product may be inferred from the product's labeling , promotional ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning